Joseph Belanoff Net Worth

The estimated Net Worth of Joseph K Belanoff is at least 34.4 百万$ dollars as of 31 July 2024. Joseph Belanoff owns over 450,000 units of Corcept Therapeutics Inc stock worth over 28,397,731$ and over the last 20 years he sold CORT stock worth over 1,047,145$. In addition, he makes 4,958,970$ as President、 Chief Executive Officer、 Director at Corcept Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Joseph Belanoff CORT stock SEC Form 4 insiders trading

Joseph has made over 75 trades of the Corcept Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 450,000 units of CORT stock worth 1,480,500$ on 31 July 2024.

The largest trade he's ever made was exercising 800,000 units of Corcept Therapeutics Inc stock on 6 July 2022 worth over 1,664,000$. On average, Joseph trades about 47,165 units every 79 days since 2004. As of 31 July 2024 he still owns at least 798,811 units of Corcept Therapeutics Inc stock.

You can see the complete history of Joseph Belanoff stock trades at the bottom of the page.

Joseph Belanoff biography

Dr. Joseph K. Belanoff M.D. serves as President, Chief Executive Officer, Director of the Company. He is a co-founder of our company and has served as a member of our Board and our Chief Executive Officer since Corcept’s inception in 1999, and as our President since 2014. Dr. Belanoff is an Adjunct Professor of Psychiatry at Stanford University (School of Medicine), where he has held positions in the Department of Psychiatry and Behavioral Sciences since 1992. Dr. Belanoff received his B.A. from Amherst College and his M.D. from Columbia University’s College of Physicians & Surgeons. Dr. Belanoff brings to our Board a deep knowledge of our research and development programs and commercial operations. He also has expertise in drug discovery and development and clinical medicine.

What is the salary of Joseph Belanoff?

As the President、 Chief Executive Officer、 Director of Corcept Therapeutics Inc, the total compensation of Joseph Belanoff at Corcept Therapeutics Inc is 4,958,970$. There are no executives at Corcept Therapeutics Inc getting paid more.

How old is Joseph Belanoff?

Joseph Belanoff is 62, he's been the President、 Chief Executive Officer、 Director of Corcept Therapeutics Inc since 2014. There are 5 older and 13 younger executives at Corcept Therapeutics Inc. The oldest executive at Corcept Therapeutics Inc is George Baker, 77, who is the Independent Director.

What's Joseph Belanoff's mailing address?

Joseph's mailing address filed with the SEC is C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK, CA, 94025.

Insiders trading at Corcept Therapeutics Inc

Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over 107,318,493$ worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth 127,133,071$ . The most active insiders traders include Patrick G Enright、Allen Andersson、Ventures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of 8,010,233$. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth 216,500$.

What does Corcept Therapeutics Inc do?

leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis

Complete history of Joseph Belanoff stock trades at Corcept Therapeutics Inc

Corcept Therapeutics Inc executives and stock owners

Corcept Therapeutics Inc executives and other stock owners filed with the SEC include:

• Joseph Belanoff,
  President, Chief Executive Officer, Director
• Andreas Grauer,
  Chief Medical Officer
• Gary Robb,
  Chief Financial Officer, Secretary
• Sean Maduck,
  Senior Vice President - Commercial
• Dr. Joseph K. Belanoff M.D.,
  Co-Founder, Pres, CEO & Director
• Dr. Joseph K. Belanoff,
  Co-Founder, Pres, CEO & Director
• Dr. Hazel Hunt Ph.D.,
  Chief Scientific Officer
• Gary Charles Robb,
  Chief Bus. Officer & Sec.
• Sean Maduck,
  Chief Commercial Officer
• James Wilson,
  Independent Chairman of the Board
• Kimberly Park,
  Independent Director
• Daniel Swisher,
  Independent Director
• David Mahoney,
  Independent Director
• George Baker,
  Independent Director
• Gillian Cannon,
  Director
• Gregg Alton,
  Independent Director
• J.D. Lyon,
  Chief Accounting Officer
• Dr. William Guyer Pharm.D.,
  Chief Devel. Officer
• Donald E. Laferle,
  Sr. VP
• Amy Flood,
  Chief HR & Communications Officer
• Dr. Christopher Shayne James M.D.,
  Director of Investor Relations
• Joseph Douglas Lyon,
  Chief Accounting Officer
• Atabak Mokari,
  Chief Financial Officer
• Renee D Gala,
  Director
• G Leonard Jr Baker,
  Director
• Daniel Bradbury,
  Director
• Robert S Fishman,
  Chief Medical Officer
• Bakker Juliet Tammenoms,
  10% owner
• Venture Partners L.P.Longit...,
  
• Venture Partners Lp Longitu...,
  
• Steven Lo,
  VP Commercial Operations
• Biopharma Partners Ii Lpalt...,
  
• Allen Andersson,
  Director
• Ventures, Llc Paperboy,
  10% owner
• Edward Penhoet,
  Director
• Patrick G Enright,
  Director
• Caroline M Loewy,
  Chief Financial Officer
• Venture Partners Lp Longitu...,
  
• Hill Ventures Sutter,
  10% owner
• Biopharma Partners Ii Lpmar...,
  
• Biopharma Partners Ii Lpalt...,
  
• Alix Marduel,
  Director
• Alan F Schatzberg,
  Director
• David B Singer,
  Director
• Fred Kurland,
  Chief Financial Officer
• Joseph L Turner,
  Director
• Anne M Le Doux,
  VP & Controller
• Joseph C Jr Cook,
  Director
• William H Jr Younger,
  10% owner
• Robert L Roe,
  President and Secretary
• Hill Venturesbaker G Leonar...,
  Director
• Jeffrey W Bird,
  10% owner
• Tench Coxe,
  10% owner
• James N White,
  10% owner
• Gregory P Sands,
  10% owner
• Hill Venturesbaker G Leonar...,
  Director
• David L Anderson,
  10% owner
• Hill Ventureswhite James N ...,
  
• Michael L Speiser,
  10% owner
• James C Gaither,
  10% owner
• David E Sweet,
  10% owner
• Hill Venturesbird Jeffrey W...,
  
• James A Harper,
  Director
• Joshua M. Murray,
  
• Atabak Mokari,
  Chief Financial Officer
• William Guyer,
  Chief Development Officer
• Hazel Hunt,
  Chief Scientific Officer